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Introduction {#sec005}
============

Helminth infections affect about one-quarter of the globe and are highly prevalent in lower to middle-income countries \[[@pntd.0008101.ref001]\]. In contrast, the prevalence of inflammatory metabolic diseases, such as Type 2 diabetes mellitus (T2DM) is high in high-income countries. The absence of exposure to helminth infections has been postulated as one mechanism to explain this markedly increased prevalence of T2DM \[[@pntd.0008101.ref002]--[@pntd.0008101.ref006]\]. Recent observational studies in India, Indonesia, China and Australia have reported that the prevalence of helminth infections was significantly lower in T2DM individuals compared to non-diabetic controls \[[@pntd.0008101.ref004], [@pntd.0008101.ref005], [@pntd.0008101.ref007], [@pntd.0008101.ref008]\], thus confirming a protective effect of helminths against T2DM pathogenesis.

Among various pathophysiological mechanisms underlying the development of T2DM, a major one is the development of chronic, low-level inflammation, also named meta-inflammation, which is characterized by a distinctly exaggerated pro-inflammatory cytokine and chemokine milieu \[[@pntd.0008101.ref009]\]. This ultimately leads to increased insulin resistance and perturbed glucose/lipid metabolism \[[@pntd.0008101.ref010]\]. In contrast, helminth infections are typically characterized by the induction of Type 2 immune responses, with elevations in Type 2 and regulatory cytokines \[[@pntd.0008101.ref011]\]. Moreover, the regulatory networks induced by helminth parasites can modulate bystander immune responses, including those of allergy and auto-immunity \[[@pntd.0008101.ref012]\].

Therefore, we postulated that one possible mechanism by which helminth infections mediate protection against T2DM is by modulating the pro-inflammatory milieu in T2DM. To test this hypothesis, we examined a panel of pro-inflammatory cytokines and chemokines before and after anthelmintic therapy in a cohort of *Strongyloides stercoralis*--diabetes individuals and compared them to diabetic individuals alone. Our data reveal that helminth infections do indeed diminish the plasma levels of cytokines and chemokines in T2DM and this is partially reversed following chemotherapy.

Material and methods {#sec006}
====================

Ethics statement {#sec007}
----------------

All the study participants were assessed as part of a natural history study protocol (12-I-073) approved by Institutional Review Boards of the National Institute of Allergy and Infectious Diseases (USA) and the National Institute for Research in Tuberculosis (India), and informed written consent was obtained from all participants. This was the same study population that was previously used for assessment of metabolic parameters \[[@pntd.0008101.ref013]\].

Study population {#sec008}
----------------

We enrolled 118 individuals comprising of 60 clinically asymptomatic *Ss*-infected individuals with T2DM (hereafter *Ss*+), and 58 individuals with T2DM and no *Ss* infection (hereafter *Ss*-) in Kanchipuram District, Tamil Nadu, South India ([Table 1](#pntd.0008101.t001){ref-type="table"}). These study participants were all recruited from a rural population by screening of individuals for helminth infection by stool microscopy and serology as described earlier \[[@pntd.0008101.ref014]--[@pntd.0008101.ref017]\]. All the recruited study participants were aged from 18 to 75 years. Individuals with any previous history of helminth infection or previous anthelmintic treatment or HIV infections, individuals who had iron deficiency anemia, alcoholism, chronic renal failure, hyperbilirubinaemia and those taking large doses of aspirin were excluded from the study. Pregnant or lactating women were excluded from the study.

10.1371/journal.pntd.0008101.t001

###### Demographic and Biochemical parameters.

![](pntd.0008101.t001){#pntd.0008101.t001g}

                       *Ss*+              *Ss*-
  -------------------- ------------------ ------------------
  M/F                  30/30              30/28
  Age                  46 (24--63)        45 (22--63)
  RBG (mg/dl)          179 (140--438)     180.5 (140--198)
  HbA1c (%)            8.57 (6.5--12.5)   8.9 (6.5--11.8)
  Urea (mg/dl)         19.5 (12.34)       21.9 (11--42)
  Creatinine (mg/dl)   0.78 (0.3--1)      0.85 (0.6--1.0)
  ALT (U/L)            17.7 (7--60)       22.4 (7--92)
  AST (U/L)            27.8 (16--110)     24.7 (11--68)

Parasitological examination and anthelmintic treatment {#sec009}
------------------------------------------------------

*Ss* infection was diagnosed by the presence of IgG antibodies to the recombinant NIE antigen as described earlier \[[@pntd.0008101.ref015], [@pntd.0008101.ref017]\]. A single stool sample was obtained and examined for intestinal helminth infection by Kato-Katz technique. Stool samples were found to be negative for other intestinal helminths by stool microscopy. Subsequently, *Ss* infection was further confirmed by specialized stool examination with nutrient agar plate cultures \[[@pntd.0008101.ref018]\]. Filarial infection was excluded in all study participants by virtue of being negative in tests for circulating filarial antigen. All *Ss*+ study participants were treated with a single dose of ivermectin (12mg) and albendazole (400 mg) and follow--up blood draws were collected six months later. Following anthelmintic treatment, parasitological examinations were repeated after 6 months to confirm successful chemotherapy.

Determination of T2DM status {#sec010}
----------------------------

Diabetes was defined as an HbA1c reading of 6.5% or greater and a random blood glucose of \>200 mg/dl, according to the American Diabetes Association criteria. All the biochemical parameters were measured after overnight fasting except random blood glucose. All of the diabetic individuals in this study were newly diagnosed and were not on any anti-diabetic medication previously. All diabetic individuals were referred to the primary health care centre for diabetic treatment.

Measurement of biochemical and anthropometric parameters {#sec011}
--------------------------------------------------------

Anthropometric measurements, including height, weight and waist circumference, and biochemical parameters, including plasma glucose, lipid profiles and HbA1c were obtained using standardized techniques as described previously \[[@pntd.0008101.ref019]\]. Serum samples were used for biochemical parameters and plasma samples were used for the other measurements.

Measurement of plasma adipocytokines and cytokine levels {#sec012}
--------------------------------------------------------

Plasma levels of cytokines: IL1α, IL-1β, IL-6, IL-12, IL-18, IL-23, IL-27, G-CSF and GM-CSF were measured using a Bioplex multiplex assay system (Bio-Rad, Hercules, CA). The levels of chemokines: CCL1, CCL2, CCL3, CCL4, CCL11, CXCL1, CXCL2, CXCL9, CXCL10 and CXCL11 were measured using Human magnetic Luminex Assay Kit from R&D Systems according to the manufacturer's protocol. Plasma level of IL-1Ra was measured using the Quantikine ELISA kit (R&D Systems) according to the manufacturer\'s instructions. We measured the *Ss*+ and *Ss*- samples side by side for each cytokine.

Statistical analysis {#sec013}
--------------------

Data analyses were performed using Graph-Pad PRISM Version 8.0 (GraphPad, San Diego, CA) and JMP14 software was used to plot Principle Component Analysis (PCA) and heatmap. Central tendency was measured using Geometric means (GM). Statistically significant differences were analyzed using Mann-Whitney U tests were used to compare *Ss*+ vs. *Ss*- and the Wilcoxon signed rank test was used to compare parameters before and after treatment followed by Holm's correction for multiple comparisons. The logistic regression was not suitable for this data to predict the group differences (i.e. *Ss+* and *Ss-*) because of the multicollinearity between most of the key variables. Those variables significantly different by Mann-Whitney test were also significantly different by the univariate logistics regression model. Sample size calculation was done to detect a significant difference (p\<0.05) among the cytokines and chemokines based on preliminary analysis between the two groups. We determined that we needed 58 individuals in each group to detect this difference with a power of 90% and a Type I error of 5%.

Results {#sec014}
=======

Study population characteristics {#sec015}
--------------------------------

The baseline demographic characteristics and biochemical parameters of *Ss*+ and *Ss*- individuals are shown in [Table 1](#pntd.0008101.t001){ref-type="table"}. As shown and as described previously \[[@pntd.0008101.ref013]\], there were no significant differences in age, sex, BMI or other biochemical parameters between the two groups.

Diminished plasma levels of pro-inflammatory cytokines in *Ss*+ individuals with T2DM {#sec016}
-------------------------------------------------------------------------------------

To determine the effect of *Ss* infection on the pro-inflammatory cytokine milieu in T2DM, we measured the plasma levels of IL-1α, IL-1β, IL-1Ra, IL-6, IL-12, IL-18, IL-23, IL-27, G-CSF and GM-CSF in *Ss*+ and *Ss*- individuals. As shown in [Fig 1](#pntd.0008101.g001){ref-type="fig"}, *Ss*+ individuals had significantly lower levels of IL-1α (GM of 350.1 pg/ml in *Ss+* vs. 458.8 pg/ml in *Ss-*; p = 0.0009), IL-1β (GM of 254.1 pg/ml in *Ss*+ vs. 342.4 pg/ml in *Ss-*; p = 0.0008), IL-6 (GM of 65.58 pg/ml in *Ss*+ vs. 133.3 pg/ml in *Ss-*; p = 0.0007), IL-12 (GM of 84.46 pg/ml in *Ss+* vs. 88.6 pg/ml in *Ss-*; p = 0.0042), IL-18 (GM of 283.7 pg/ml in *Ss+* vs. 412.1 pg/ml in *Ss-*; p = 0.0260), IL-23 (GM of 244.1 pg/ml in *Ss*+ vs. 298.2 pg/ml in *Ss-*; p = 0.0380), IL-27 (GM of 323.8 pg/ml in *Ss*+ vs. 516.3 pg/ml in *Ss-*; p = 0.0483), G-CSF (GM of 68.46 pg/ml in *Ss*+ vs. 114.8 pg/ml in *Ss-*; p = 0.0426), and GM-CSF (GM of 78.89 pg/ml in *Ss+* vs. 95.22 pg/ml in *Ss-*; p = 0.0448) in comparison with *Ss*- individuals. In contrast, *Ss*+ individuals had significantly higher levels of IL-1Ra (GM of 267.6 pg/ml in *Ss+* vs. 203.4 pg/ml in *Ss-*; p = 0.0004). Thus, *Ss* infection appears to modulate the systemic pro-inflammatory cytokine milieu in T2DM.

![Diminished plasma levels of pro-inflammatory cytokines in *Ss*+ individuals with T2DM.\
Plasma levels of IL1-α, IL1-β, IL-1Ra, IL-6, IL-12, IL-18, IL-23, IL-27, G-CSF and GM-CSF cytokines were measured in *Ss*+ and *Ss*- individuals. Each dot is an individual subject with the bar representing the geometric mean (GM). p values were calculated using the Mann-Whitney U tests followed by Holm's correction for multiple comparisons.](pntd.0008101.g001){#pntd.0008101.g001}

Diminished plasma levels of pro-inflammatory chemokines in *Ss*+ individuals with T2DM {#sec017}
--------------------------------------------------------------------------------------

To determine the effect of *Ss* infection on the pro-inflammatory chemokine milieu in T2DM, we measured the plasma levels of CCL1, CCL2, CCL3, CCL11, CXCL1, CXCL2, CXCL9, CXCL10 and CXCL11 in *Ss*+ and *Ss*- individuals. As shown in [Fig 2](#pntd.0008101.g002){ref-type="fig"}, *Ss*+ individuals had significantly lower levels of CCL1 (GM of 878.3 pg/ml in *Ss*+ vs. 1095 pg/ml in *Ss-*; p = 0.0010), CCL2 (GM of 227.4 pg/ml in *Ss*+ vs. 277.9 pg/ml in *Ss-*; p = 0.0045), CCL3 (GM of 223.6 pg/ml in *Ss*+ vs. 300.9 pg/ml in *Ss-*; p = 0.0012), CCL11 (GM of 406.9 pg/ml in *Ss*+ vs. 521.2 pg/ml in *Ss*-; p = 0.0091), CXCL1 (GM of 711.4 pg/ml in *Ss*+ vs. 1040 pg/ml in *Ss-*; p = 0.0318), CXCL2 (GM of 383.2 pg/ml in *Ss*+ vs. 578.1 pg/ml in *Ss-*; p = 0.0410), CXCL8 (GM of 291.1 pg/ml in *Ss*+ vs. 410.3 pg/ml in *Ss-*; p = 0.0468), CXCL9 (GM of 432.5 pg/ml in *Ss*+ vs. 620 pg/ml in *Ss-*; p = 0.0438), CXCL10 (GM of 347.7 pg/ml in *Ss*+ vs. 479.5 pg/ml in *Ss-*; p = 0.0430) and CXCL11 (GM of 313.2 pg/ml in *Ss*+ vs. 505 pg/ml in *Ss-*; p = 0.0360) in comparison with *Ss*- individuals. Thus, *Ss* infection also appears to modulate the pro-inflammatory chemokine milieu in T2DM.

![Diminished plasma levels of pro-inflammatory chemokines in *Ss*+ individuals with T2DM.\
Plasma levels of CCL1, CCL2, CCL3, CCL11, CXCL1, CXL2, CXCL8, CXCL9, CXCL10 and CXCL11 chemokines were measured in *Ss*+ and *Ss*- individuals. Each dot is an individual subject with the bar representing the geometric mean (GM). p values were calculated using the Mann-Whitney U tests followed by Holm's correction for multiple comparisons.](pntd.0008101.g002){#pntd.0008101.g002}

Anthelmintic treatment significantly increases the plasma cytokine levels in T2DM {#sec018}
---------------------------------------------------------------------------------

To determine the effect of anthelmintic treatment on the pro-inflammatory cytokine milieu in T2DM, we measured the plasma levels of IL1α, IL-1β, IL-1Ra, IL-6, IL-12, IL-18, IL-23, IL-27, G-CSF and GM-CSF in *Ss+* individuals before (pre-T) and 6 months after anthelmintic treatment (post-T). At post-T, the levels of IL1α (GM of 350.1 pg/ml in pre-T vs. 496 pg/ml in post-T; p = 0.0009), IL-1β (GM of 254.1 pg/ml in pre-T vs. 268.7 pg/ml in post-T; p = 0.0008), IL-6 (GM of 65.58 pg/ml in pre-T vs. 78.4 pg/ml in post-T; p = 0.0007), IL-12 (GM of 84.76 pg/ml in pre-T vs. 90.14 pg/ml in post-T; p = 0.0006), IL-18 (GM of 283.7 pg/ml in pre-T vs. 374.9 pg/ml in post-T; p = 0.0005), IL-23 (GM of 244.1 pg/ml in pre-T vs. 312.5 pg/ml in post-T; p = 0.0004), IL-27 (GM of 323.8 pg/ml in pre-T vs. 444.3 pg/ml in post-T; p = 0.0006), G-CSF (GM of 68.47 pg/ml in pre-T vs. 88.41 pg/ml in post-T; p = 0.0044) and GM-CSF (GM of 78.89 pg/ml in pre-Tvs. 92.99 pg/ml in post-T; p = 0.0427) were all significantly increased in comparison to pre-T levels ([Fig 3](#pntd.0008101.g003){ref-type="fig"}). In contast, the levels of IL1Ra (GM of 267.6 pg/ml in pre-T vs. 250.2 pg/ml in post-T; p = 0.0001) was significantly decreased at post-T. Thus, anthelmintic treatment partially restores the pro-inflammatory cytokine milieu in T2DM.

![Anthelmintic treatment significantly increased the plasma cytokine levels in T2DM.\
Plasma levels of IL1-α, IL1-β, IL-1Ra, IL-6, IL-12, IL-18, IL-23, IL-27, G-CSF and GM-CSF cytokines were measured in *Ss*+ individuals pretreatment \[Pre-T\] and 6 months following treatment \[post-T\] were measured. The data are represented as line graphs with each line representing a single individual. p values were calculated using the Wilcoxon signed rank test followed by Holm's correction for multiple comparisons.](pntd.0008101.g003){#pntd.0008101.g003}

Anthelmintic treatment significantly increases the plasma chemokine levels in T2DM {#sec019}
----------------------------------------------------------------------------------

To determine the effect of anthelmintic treatment on the pro-inflammatory chemokine milieu in T2DM, we measured the plasma levels of CCL1, CCL2, CCL3, CCL11, CXCL1, CXCL2, CXCL9, CXCL10 and CXCL11 in *Ss+* individuals before (pre-T) and 6 months after anthelmintic treatment (post-T). At post-T, the levels of CCL1 (GM of 878.3 pg/ml in pre-T vs. 939.2 pg/ml in post-T; p = 0.0009), CCL2 (GM of 227.4 pg/ml in pre-T vs. 272.1 pg/ml in post-T; p = 0.0008), CCL3 (GM of 223.6 pg/ml in pre-T vs. 282.7 pg/ml in post-T; p = 0.0007), CXCL1 (GM of 711.4 pg/ml in pre-T vs. 763.8 pg/ml in post-T; p = 0.0006), CXCL2 (GM of 383.2 pg/ml in pre-T vs. 512.9 pg/ml in post-T; p = 0.0005), CXCL8 (GM of 292.1 pg/ml in pre-T vs. 327.9 pg/ml in post-T; p = 0.0004), CXCL9 (GM of 432.5 pg/ml in pre-T vs. 546.6 pg/ml in post-T; p = 0.0009), CXCL10 (GM of 347.7 pg/ml in pre-T vs. 408.7 pg/ml in post-T; p = 0.0220) and CXCL11 (GM of 313.2 pg/ml in pre-T vs. 332.7 pg/ml in post-T; p = 0.0318) were all significantly increased in comparison to pre-T levels ([Fig 4](#pntd.0008101.g004){ref-type="fig"}). Thus, anthelmintic treatment partially restores the pro-inflammatory chemokine milieu in T2DM.

![Anthelmintic treatment significantly increased the plasma chemokine levels in T2DM.\
Plasma levels of CCL1, CCL2, CCL3, CCL11, CXCL1, CXL2, CXCL8, CXCL9, CXCL10 and CXCL11 chemokines were measured in *Ss*+ individuals pretreatment \[Pre-T\] and 6 months following treatment \[post-T\] were measured. The data are represented as line graphs with each line representing a single individual. p values were calculated using the Wilcoxon signed rank test followed by Holm's correction for multiple comparisons.](pntd.0008101.g004){#pntd.0008101.g004}

PCA analysis and heatmaps reveal trends in cytokine and chemokine milieu in helminth-T2DM co-morbidity {#sec020}
------------------------------------------------------------------------------------------------------

To assess the trends in cytokine and chemokine discrimination between *Ss+* (both pre- and post-treatment) and *Ss-* individuals, we plotted PCA with different inputs. As shown in [Fig 5A](#pntd.0008101.g005){ref-type="fig"}, PCA analysis shows that cytokines and chemokines cluster differently between *Ss+* (pre-treatment) and *Ss-* individuals. In contrast, as shown in [Fig 5B](#pntd.0008101.g005){ref-type="fig"}, PCA analysis shows very little clustering between *Ss+* (post-treatment) and *Ss-* individuals. Finally, heatmap analysis using the geometric mean values of cytokine and chemokine levels shows the highly upregulated expression profile in *Ss-* individuals and the moderately upregulated expression profile in post-T individuals compared to pre-T *Ss+* individuals ([Fig 5C](#pntd.0008101.g005){ref-type="fig"}). Thus, these analysis help reveal the power of cytokines and chemokines to demarcate the effect of *Ss* infection on T2DM.

![Principal component Analysis (PCA) and heatmaps depicting circulating levels of cytokines and chemokines in *Ss*+ (pre- and post-treatment) and *Ss*- individuals.\
**(A and B)** Principal component analysis (PCA) was performed to show the distribution of data from the combination of two groups *Ss*+ (blue circles) and *Ss*- (red circles)(A); and Post-T *Ss*+ (blue circles) and *Ss*- (red circles) (B). The PCA represents the two principal components of variation. (C) Heatmaps depicting the circulating levels of cytokines and chemokines in *Ss*+ (pre- and post-treatment) and *Ss*- individuals. Data (and scale) are log10 geometric mean fold change for each of the analytes measured for each of the groups. Plasma levels for *Ss*+, post treated and *Ss*- individuals were shown respectively, in which each row stands for a sample and each column stands for a cytokine and chemokines. Red color represents the highest values whereas blue color indicates the lowest values measured for each analyte.](pntd.0008101.g005){#pntd.0008101.g005}

Discussion {#sec021}
==========

During the last few years, several studies have highlighted the important role played by the immune system in regulating metabolic homeostasis in both animal models and human disease \[[@pntd.0008101.ref020], [@pntd.0008101.ref021]\]. The cross-talk between innate and adaptive immune cell subsets on the one hand and the metabolic cells on the other leads to a complex network governing metabolic functions both at a systemic and tissue specific level \[[@pntd.0008101.ref020], [@pntd.0008101.ref021]\]. Interestingly, regulatory pathways induced by chronic helminth infections have been associated with reduced insulin resistance and a lower prevalence of metabolic syndrome and T2DM \[[@pntd.0008101.ref004], [@pntd.0008101.ref005], [@pntd.0008101.ref007], [@pntd.0008101.ref008], [@pntd.0008101.ref013], [@pntd.0008101.ref022]\], suggesting that helminth-mediated immunomodulation affords a protective effect against metabolic diseases \[[@pntd.0008101.ref023]\].

Elevated levels of pro-inflammatory cytokines have been described in both cross-sectional and prospective studies in T2DM \[[@pntd.0008101.ref024]--[@pntd.0008101.ref026]\]. Moreover, heightened levels of IL-1β and IL-6 are predictive of T2DM \[[@pntd.0008101.ref025], [@pntd.0008101.ref027]\]. In addition, other pro-inflammatory cytokines such as IL-1α, IL-12 and IL-18 are linked to pancreatic islet inflammation \[[@pntd.0008101.ref009], [@pntd.0008101.ref028]\]. IL-23 is known to induce beta cell oxidative and ER stress in diabetic animal models \[[@pntd.0008101.ref029]\], while IL-27 might play a pathogenic role \[[@pntd.0008101.ref030]\], and IL-12 contributes to angiogenesis \[[@pntd.0008101.ref031]\]. Similarly, GM-CSF and G-CSF also contribute to the pathogenesis of inflammation in T2DM \[[@pntd.0008101.ref009], [@pntd.0008101.ref028]\]. The elevated levels of these pro-inflammatory cytokines in T2DM is thought to reflect the activation of innate immune cells driven by increased nutrient concentrations. The sum total of these effects contributes to glucotoxicity, lipotoxicity, oxidative and ER stress of pancreatic islets in T2DM \[[@pntd.0008101.ref010]\]. Similar to cytokines, a variety of chemokines are also involved in islet inflammation, oxidative and ER stress and dysglycemia. These include CC and CXC chemokines including CCL1, CCL2, CCL3, CCL11, CXCL1, CXCL2, CXCL9, CXCL10 and CXCL11 \[[@pntd.0008101.ref009], [@pntd.0008101.ref028]\]. Our data highlight a novel feature of helminth--T2DM interaction in demonstrating the depression of circulating levels of all of the cytokines and chemokines mentioned above. Thus, coexistent chronic infection with *Ss* is associated with a dampened inflammatory cytokine and chemokine response in T2DM. Thus, our study provides a plausible biological mechanism for the observational studies showing a protective effect of helminth infection against T2DM.

While an inverse association has been reported between infection with *Schistosoma japonicum* and *Ss* and the prevalence of metabolic syndrome and T2DM, anthelmintic therapy was shown to impair metabolic homeostasis as characterized by increased homeostatic model assessment for insulin resistance (HOMA-IR) and haemoglobin A1c \[[@pntd.0008101.ref004], [@pntd.0008101.ref013], [@pntd.0008101.ref022]\]. Our study again offers a plausible biological mechanism for this effect by demonstrating that anthelmintic treatment restores (at least partially) the elevated levels of pro-inflammatory cytokines and chemokines in T2DM. As clearly demonstrated by the PCA and heatmap analysis, anthelmintic treatment alone does not cause a complete reversion to the systemic levels of cytokines and chemokines seen in helminth uninfected T2DM individuals. This is possibly due to the fact that helminth induced immunomodulation might require more time to return to homeostasis.

The limitations of the study include the absence of oral glucose tolerance testing for diabetes, the moderate sample size and the absence of testing for protozoa. Nevertheless, our study offers novel insights into the immunological interactions between helminth infections and metabolic disorders. In summary, our study demonstrates that *Ss* infection may provide a degree of protection from the pathology associated with T2DM by modulating the surrounding cytokine and chemokine milieu. Our data also suggest that helminth derived molecules or even helminth infection (per se) could offer novel therapeutic approaches to treating inflammatory metabolic diseases.
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\- For the analysis of the comparison of the groups in relation to the dosages, how was the comparison made? using average or median? looking at the figures some analysis seems that the confidence interval overlaps between the groups and would not have significant difference.

\- Why was no analysis of clustered cytokines performed? What relationship between them?

Reviewer \#3: -Are the objectives of the study clearly articulated with a clear testable hypothesis stated?
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-Is the study design appropriate to address the stated objectives?
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-Is the population clearly described and appropriate for the hypothesis being tested?
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-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?
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-Were correct statistical analysis used to support conclusions?

YES

-Are there concerns about ethical or regulatory requirements being met?

YES
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**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: Figure 3 and 4 are visually not well presented. It would be helpful to see the mean values of pre and post, and may be have different colors for changes going up or down

Reviewer \#2: -Does the analysis presented match the analysis plan? NO

\- -Are the results clearly and completely presented? NO

\- -Are the figures (Tables, Images) of sufficient quality for clarity? YES

Reviewer \#3: -Does the analysis presented match the analysis plan?

YES

-Are the results clearly and completely presented?
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-Are the figures (Tables, Images) of sufficient quality for clarity?
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**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: Yes

Reviewer \#2: -Are the conclusions supported by the data presented? NO

-Are the limitations of analysis clearly described? NO

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? YES

-Is public health relevance addressed? NO

Reviewer \#3: -Are the conclusions supported by the data presented?

YES, but the author did not measure any anti inflammatory markers

-Are the limitations of analysis clearly described?

NO, the author should add the limitations of thi study

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

YES

-Is public health relevance addressed?
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**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: See above my suggestions which I consider as minor

Reviewer \#2: (No Response)

Reviewer \#3: Method Section:

For the determination of T2DM status, the author used HbA1c and Random Blood Glucose. If possible, the author should also describe other factors that might affect HbA1c level in the study population eg anemia, etc.

For the measurement of cytokines level, the author should describe whether the measurements were done in paired samples ( SS pos and SS neg side by side for each sample)?

The author should also describe about other factors that might affect inflammatory markers, eg infections, medications, etc \-- and whether this has been addressed by excluding those subjects or adjust for these factors in the analysis
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**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: This is a very interesting observational study, which may be a starting point for further studies and drug development. The hypothesis is clear, the data are solid and the manuscript is well written. The major limitation is that the study is purely correlative, but it does not take away from its originality.

Reviewer \#2: (No Response)

Reviewer \#3: This is a well written article. The author describes the fact that helminth infections could modulate systemic pro-inflammatory cytokines and chemokines in newly diagnosed diabetes.

However, several issues need to be addressed.

Major

Why did the author did not measure any anti-inflammatory cytokines or chemokines?

Minor comments

The author should also describe about other factors that might affect inflammatory markers, eg infections, medications, etc \-- and whether this has been addressed by excluding those subjects or adjust for these factors in the analysis

For the measurement of cytokines level, the author should describe whether the measurements were done in paired samples ( SS pos and SS neg side by side for each sample)?

For the determination of T2DM status, the author used HbA1c and Random Blood Glucose. If possible, the author should also describe other factors that might affect HbA1c level in the study population eg anemia, etc.
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We are pleased to inform you that your manuscript \'Helminth infection modulates systemic pro-inflammatory cytokines and chemokines implicated in Type 2 diabetes mellitus pathogenesis\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch within two working days with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.
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Dear Dr. Babu,

We are delighted to inform you that your manuscript, \"Helminth infection modulates systemic pro-inflammatory cytokines and chemokines implicated in Type 2 diabetes mellitus pathogenesis,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.
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